David Kessler likely to retire from the FDA:
This article was originally published in Clinica
After six years as commissioner of the US FDA, The Washington Times reports that David Kessler intends to join the exodus of top-level officials from President Clinton's administration. Dr Kessler has been assiduous in efforts to have nicotine classified as a drug and thus made subject to regulation. He has also led attempts to speed the agency's approvals processes for drugs and devices. Dr Kessler's spokesman told Clinica that the commissioner's departure was not imminent, but that Dr Kessler had accomplished all his long term goals for the agency.
You may also be interested in...
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
EURLs have been a critical missing element of the IVDR for assessing the higher-risk class D IVDs. Two new implementing regulations, on fees and tasks, bring them closer to designation.
It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?